Smarter Cancer Care
In collaboration with thousands of physicians around the world, over one million patients improved their outcomes with the Oncotype IQ portfolio of genomic tests.
Learn More

SABCS 2020 Virtual Symposium

December 8-12, 2020

Join us for a variety of engaging speakers and presentations, including our Industry Product Theater: "Yes or No? Answering chemotherapy and endocrine therapy questions through a case-based discussion with the Oncotype DX® test".

Biomarkers for Advanced-Stage Prostate Cancer Patients

Wednesday, December 9th, 12PM PT / 3PM ET

Join our live webinar focused on how the AR-V7 biomarker can help physicians personalize treatment decisions in patients with metastatic castration-resistant prostate cancer with speaker Dr. Scott B. Sellinger.

New Genomic Test

Oncotype MAP Pan-Cancer Tissue Test

A rapid, comprehensive genomic profiling panel to aid therapy selection for a breadth of solid tumor types.

Molecular Profiling in Lung Cancer Webinar

Available On-Demand

View our webinar: Optimizing Molecular Profiling in Non-Small Cell Lung Cancer, explore recent advances in molecular testing, emerging NSCLC biomarkers of disease, and real-world case studies in clinical practice.
Real People.
Real Results.
When Amy was diagnosed with breast cancer, she was scared. Her Oncotype DX Breast DCIS Score result made her feel in control.
Learn More
Latest TAILORx Data
The landmark TAILORx results provide definitive answers on which early stage ER+, HER2-, N0 breast cancer patients can benefit from chemotherapy.
Learn More
Our Response to COVID-19
Oncotype DX tests remain readily available and that our laboratory continues to operate. Our patient-critical work teams continue to operate, following all safety procedures and practices.
LEARN MORE
Healthcare Savings
How much do ineffective cancer treatments cost the healthcare system? In the US alone, Oncotype IQ tests have saved more than $3.5 billion.
Learn More

Stay in Touch

Have questions? We're here to help.

 Contact Us
Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Oncotype MAP, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc. Exact Sciences is a trademark of Exact Sciences Corporation.
Making cancer care smarter.™
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.